APLS Apellis Pharmaceuticals Inc

Price (delayed)

$39.53

Market cap

$4.8B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.45

Enterprise value

$4.58B

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims ...

Highlights
The EPS is up by 45% year-on-year and by 22% since the previous quarter
APLS's net income is up by 40% year-on-year and by 21% since the previous quarter
The company's quick ratio has shrunk by 52% YoY but it rose by 22% QoQ
The equity has increased by 37% since the previous quarter but it has declined by 35% year-on-year
The company's gross margin fell by 2.3% YoY

Key stats

What are the main financial stats of APLS
Market
Shares outstanding
121.37M
Market cap
$4.8B
Enterprise value
$4.58B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
17.87
Price to sales (P/S)
9.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.74
Earnings
Revenue
$524.07M
EBIT
-$386.23M
EBITDA
-$384.48M
Free cash flow
-$550.81M
Per share
EPS
-$3.45
Free cash flow per share
-$4.48
Book value per share
$2.21
Revenue per share
$4.26
TBVPS
$6.77
Balance sheet
Total assets
$831.93M
Total liabilities
$565.25M
Debt
$109.14M
Equity
$266.68M
Working capital
$596.14M
Liquidity
Debt to equity
0.41
Current ratio
3.77
Quick ratio
2.76
Net debt/EBITDA
0.57
Margins
EBITDA margin
-73.4%
Gross margin
86.5%
Net margin
-79.6%
Operating margin
-77.1%
Efficiency
Return on assets
-49.8%
Return on equity
-160.7%
Return on invested capital
-126.5%
Return on capital employed
-62.6%
Return on sales
-73.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

APLS stock price

How has the Apellis Pharmaceuticals stock price performed over time
Intraday
1.65%
1 week
9.08%
1 month
-6.99%
1 year
-53.5%
YTD
-33.96%
QTD
3.05%

Financial performance

How have Apellis Pharmaceuticals's revenue and profit performed over time
Revenue
$524.07M
Gross profit
$453.16M
Operating income
-$404.13M
Net income
-$417.27M
Gross margin
86.5%
Net margin
-79.6%
The company's net margin has surged by 88% YoY and by 40% QoQ
APLS's operating margin has surged by 87% year-on-year and by 41% since the previous quarter
APLS's net income is up by 40% year-on-year and by 21% since the previous quarter
APLS's operating income is up by 37% year-on-year and by 22% since the previous quarter

Growth

What is Apellis Pharmaceuticals's growth rate over time

Valuation

What is Apellis Pharmaceuticals stock price valuation
P/E
N/A
P/B
17.87
P/S
9.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.74
The EPS is up by 45% year-on-year and by 22% since the previous quarter
The equity has increased by 37% since the previous quarter but it has declined by 35% year-on-year
The P/B is 37% less than the last 4 quarters average of 28.3 and 29% less than the 5-year quarterly average of 25.3
The stock's price to sales (P/S) is 65% less than its last 4 quarters average of 26.8
APLS's revenue is up by 32% since the previous quarter

Efficiency

How efficient is Apellis Pharmaceuticals business performance
The return on sales has surged by 88% year-on-year and by 41% since the previous quarter
The company's return on invested capital rose by 47% YoY and by 36% QoQ
APLS's ROA is up by 35% year-on-year and by 18% since the previous quarter
APLS's ROE is up by 29% YoY and by 10% QoQ

Dividends

What is APLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APLS.

Financial health

How did Apellis Pharmaceuticals financials performed over time
Apellis Pharmaceuticals's total assets is 47% more than its total liabilities
The company's quick ratio has shrunk by 52% YoY but it rose by 22% QoQ
The company's current ratio fell by 45% YoY but it rose by 22% QoQ
The company's debt is 59% lower than its equity
The debt to equity has soared by 52% year-on-year but it has declined by 28% since the previous quarter
The equity has increased by 37% since the previous quarter but it has declined by 35% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.